The VENTANA PD-L1 Portfolio
Informing decisions | Empowering choices
VENTANA PD-L1 assays generate results you can trust, so that you can make timely diagnostic decisions and therapeutic choices. We support your expertise by providing you with the tools that you need to successfully implement these assays into your laboratory and interpret them proficiently.
PD-L1 predictive assays
VENTANA predictive assays identify patients who are most likely to respond to specific therapies.
VENTANA PD-L1 (SP142) Assay gives you the confidence to appropriately identify urothelial carcinoma (UC) and non-small cell lung cancer (NSCLC) patients most likely to benefit from TECENTRIQ® (atezolizumab).
VENTANA PD-L1 (SP263) Assay guides immunotherapy decisions by identifying:
- Non-small cell lung cancer (NSCLC) patients eligible for treatment with KEYTRUDA® (pembrolizumb) [CE mark only, not FDA approved]
- Non-squamous NSCLC patients most likely to benefit from OPDIVO® (nivolumab) [CE mark only, not FDA approved]
- Urothelial carcinoma (UC) patients most likely to benefit from IMFINZI™ (durvalumab) [FDA approved in the US]
PD-L1 analytic assays
VENTANA analytic assays evaluate for expression of PD-L1 in tumor and immune cells in the context of the tumor microenvironment.
VENTANA PD-L1 (SP142) IHC Assay is highly specific, reproducible and designed to enhance visual contrast of immune cell staining within the tumor microenvironment. CE Marked.
VENTANA PD-L1 (SP263) Rabbit Monoclonal Primary Antibody was the first ready-to-use assay that allowed you to evaluate the expression of PD-L1 protein in tumor and immune cells using the OptiView DAB IHC Detection Kit. Available for sale in the US and CE Marked.